or
Remember me
Destroying Cancer at the Speed of Light® Clinical Study Underway (75 of 100 Patients Treated) Expected to complete enrollment at the end of 2024 Expected to complete study at the end of 2026
Back
Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru(II) polypyridyl complexes have emerged as promising systems for both PDT and PCT. Their rich photochemical and photophysical properties derive from a variety of excited-state electronic configurations accessible with visible and near-infrared light, and these properties can be exploited for both energy- and electron-transfer processes that can yield highly potent oxygen-dependent and/or oxygen-independent photobiological activity. Selected examples highlight the use of rational design in coordination chemistry to control the lowest-energy triplet excited-state configurations for eliciting a particular type of photoreactivity for PDT and/or PCT effects. These principles are also discussed in the context of the development of TLD1433, the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial. The design of TLD1433 arose from a tumor-centered approach, as part of a complete PDT package that includes the light component and the protocol for treating non-muscle invasive bladder cancer. Briefly, this review summarizes the challenges to bringing PDT into mainstream cancer therapy. It considers the chemical and photophysical solutions that transition metal complexes offer, and it puts into context the multidisciplinary effort needed to bring a new drug to clinical trial.
A daily snapshot of everything from market open to close.
The Road to Saving Lives: Clinical Study Underway
Address: 41 Hollinger Road Toronto, ON M4B 3G4 Canada Toll Free: 1-866-THE-LASE (843-5273) Local Phone: 416-699-LASE (5273) Email: info@theralase.com Fax: 416-699-5250